Masimo Co. (NASDAQ:MASI) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans trimmed its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 99.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,373 shares of the medical equipment provider's stock after selling 1,206,984 shares during the quarter. Thrivent Financial for Lutherans' holdings in Masimo were worth $1,383,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. NBC Securities Inc. raised its position in Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 73 shares during the period. GAMMA Investing LLC raised its holdings in Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock worth $44,000 after buying an additional 200 shares during the last quarter. HHM Wealth Advisors LLC boosted its stake in Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider's stock worth $79,000 after buying an additional 125 shares during the period. Finally, Lazard Asset Management LLC boosted its stake in Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider's stock worth $85,000 after buying an additional 573 shares during the period. Institutional investors own 85.96% of the company's stock.

Analysts Set New Price Targets

MASI has been the subject of several analyst reports. Raymond James upgraded shares of Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 target price for the company in a report on Wednesday, November 6th. Wells Fargo & Company raised their price objective on shares of Masimo from $160.00 to $171.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Wednesday, November 6th. BTIG Research raised their price target on Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Finally, Stifel Nicolaus reaffirmed a "buy" rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $167.00.

Masimo Stock Up 1.0 %

Shares of MASI stock traded up $1.65 during mid-day trading on Friday, hitting $172.54. The stock had a trading volume of 240,979 shares, compared to its average volume of 680,424. Masimo Co. has a 12-month low of $91.60 and a 12-month high of $178.27. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The firm's 50-day moving average is $149.24 and its two-hundred day moving average is $129.81. The firm has a market capitalization of $9.24 billion, a P/E ratio of 118.99 and a beta of 0.97.

Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million for the quarter, compared to analysts' expectations of $502.87 million. During the same period in the prior year, the business earned $0.63 EPS. The firm's quarterly revenue was up 5.4% on a year-over-year basis. On average, analysts predict that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.